Jazz Pharmaceuticals plc (JAZZ)
NASDAQ • Healthcare
Last close at November 11, 2026 at 21:00 UTC
Metrics Over Time
Where the Money Goes
Q3 2026In plain terms: out of every $100 in revenue, Jazz Pharmaceuticals plc currently loses $39.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Jazz Pharmaceuticals’ preliminary third fiscal quarter of 2026 results showed revenue topping consensus, with sales up 10.4% year over year to about $1.2 billion (up from about $1.1 billion a year ago) as reported on November 2, 2026. On the top line, revenue of $1.243 billion topped the $1.208 billion estimate, +2.9%. The company generated about $506.1 million of operating cash flow during the quarter. Looking ahead, next-period consensus calls for EPS of $6.84 on revenue of $1.245 billion.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a biotechnology company listed on NASDAQ as JAZZ that develops and markets medicines for sleep disorders, epilepsy, and cancer across rare and specialty diseases. Its portfolio spans rare and specialty diseases, and the business generated $4.3 billion in FY2025 revenue.
Today's Snapshot
JAZZ opened slightly higher at 248.80, while its sector was flat. Piper Sandler, an analyst, raised Jazz Pharmaceuticals’ price target to $330, citing its cancer drug Ziihera.
Trading Volume
Below 10d avg (854.0K)
92.5K
vs S&P 500 Today
Underperforming Market
-0.77%
Updated: November 12, 2026 at 15:56 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$213.77 - $235.14Buy
- RSI (14)62.59Neutral
- Stochastic %K (14, 3, 3)93.89Sell
- MACD Level (12, 26)5.12Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.